$DCAC Daniels Corporate Advisory Co. Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Lee Adams
174
$DCAC Daniels Corporate Advisory Co. Inc.

http://www.danielscorporateadvisoryco.com/

Founded in 2002, Daniels (OTC: DCAC) is a corporate strategy firm servicing the myriad needs of small, growing public and private companies through customized financial, operational and business strategy initiatives. From securing growth capital to the placement of senior-level team members, Daniels provides clients with unique and appropriate strategies designed to incubate and accelerate their growth in new or existing niche markets. These strategies include joint-ventures, marketing opportunities, partnerships, and potential acquisitions, just to name a few.

To the most promising of client opportunities, Daniels offers growth and implementation capital either directly and/or through a joint-venture with members of our capital referral network – always within a relatively non-dilutive deal structure.

Whether generic or acquisitive in nature, the optimum deal structure to accelerate growth is designed to limit the amount of time necessary for the client to achieve the requirements to list on a major US Stock Exchange (American/Small Cap NASDAQ). Daniels strives to complete the process within 14 to 24 months following its initial engagement with the client.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FDA Greenlights Kisqali®: A Major Step for Breast Cancer Care

Updated Category News Views 203

Kisqali® Receives FDA Approval for Early Breast Cancer Treatment Novartis has some exciting news for oncology: the US Food and Drug Administration (FDA) has officially approved Kisqali® (ribociclib) as a treatment for patients diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer...

Continue Reading
Ålandsbanken Abp Launches SEK 350M Additional Tier 1 Notes Series

Updated Category News Views 162

Ålandsbanken Abp Issues SEK 350,000,000 Additional Tier 1 Notes Ålandsbanken Abp, a prominent player in the banking industry, recently made waves in the financial market by issuing Additional Tier 1 floating rate notes amounting to SEK 350,000,000. The issuance marks a significant step in Ålandsbanken's strategic move to strengthen its capital position and enhance its...

Continue Reading
Harbour BioMed's 2025 Achievements and Future Prospects

Updated Category News Views 249

Harbour BioMed Achieves Significant Milestones in Interim Results Harbour BioMed (HKEX: 02142) is a prominent biopharmaceutical company focused on developing innovative antibody therapeutics, particularly in the fields of immunology and oncology. The company shared its impressive interim results for the first half of the year, showcasing remarkable growth and strategic...

Continue Reading
Innovative Investment Fuels Okika Devices' Future Growth Strategy

Updated Category News Views 187

Strategic Investment Boosts Okika Devices Advancement Colorado ONE Fund, which is part of the ONE Funds initiative, has made a major investment in Okika Devices, a company recognized for its innovation in Field Programmable Analog Array (FPAA) technology. This investment aligns with Colorado ONE Fund's mission to support technologies that advance the local innovation...

Continue Reading
Investors Take Note: Legal Options for Shareholders Explored

Updated Category News Views 61

Exploring Legal Options for Investors in Major Companies In recent developments, Halper Sadeh LLC, a reputable law firm focusing on investor rights, is carefully examining three significant companies for potential violations of federal securities laws. This investigation centers around the actions and decisions made by these firms, which may affect shareholders' rights...

Continue Reading